Fig. 1: LSD1 inhibition in T cells enhances antitumor immunity in MC38 tumor model.
From: LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
a, b Tumor growth (a) and survival curves (b) of Lsd1f/f and Cd4-Cre+Lsd1f/f mice subcutaneously inoculated with MC38 tumor cells (n = 7 per group). c, d Tumor growth (c) and survival curves (d) of wildtype mice inoculated with MC38 tumor cells and treated with LSD1 inhibitor GSK2879552 or vehicle control daily for 2 weeks (arrow line). e The real-time qPCR analysis of IFN-related genes in cultured MC38 cells treated with 2 μM GSK-LSD1, 0.5 μM ORY1001 or vehicle control for 5 days (n = 3). f Tumor growth curves of wildtype mice inoculated with wildtype parental or Lsd1 KO MC38 tumor cells. g, h Tumor growth (g) and survival curves (h) of TCRα KO mice inoculated with wildtype MC38 tumor cells and treated with GSK2879552 or vehicle control daily for 2 weeks (arrow line, vehicle group, n = 7; GSK2879552 group, n = 6). i Flow cytometry analysis of B2m expression by WT and B2m KO MC38 cells. j, k Tumor growth (j) and survival curves (k) of Lsd1f/f and Cd4-Cre+Lsd1f/f mice inoculated with B2m KO MC38 tumor cells (n = 5 per group). Data represent two independent experiments and are presented as mean ± SEM (standard error of the mean, a, c, f, g, j) or mean ± SD (standard deviation, e). Sample sizes are as indicated. Statistical significance was determined by two-sided unpaired t test (a, c, e–g, j) or log-rank test (b, d, h, k). Source data are provided as a Source data file.
